Fibrocell to Host Conference Call & Webcast for Full Year 2018 Financial Results and Recent Highlights on March 27, 2019
20 mars 2019 08h00 HE
|
Fibrocell Science Inc.
- Company to provide update on Type B meeting with FDA on Phase 3 clinical trial design for FCX-007 gene therapy candidate for recessive dystrophic epidermolysis bullosa (RDEB) - - Company to...
Fibrocell to Present at 21st Annual BIO CEO & Investor Conference
06 févr. 2019 08h00 HE
|
Fibrocell Science Inc.
EXTON, Pa., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell to Present at Phacilitate Leaders World 2019
16 janv. 2019 08h00 HE
|
Fibrocell Science Inc.
EXTON, Pa., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Receives $900,000 Investment from EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation
11 déc. 2018 08h00 HE
|
Fibrocell Science Inc.
EXTON, Pa., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights
13 nov. 2018 08h00 HE
|
Fibrocell Science Inc.
- Company to Host Conference Call and Webcast Today at 8:30 a.m. EST – - Announces patient enrollment completed in Phase 2 of Phase 1/2 clinical trial for FCX-007 for recessive dystrophic...
Fibrocell to Host Conference Call and Webcast on Tuesday, November 13, 2018 to Discuss Third Quarter 2018 Financial Results and Recent Highlights
08 nov. 2018 08h00 HE
|
Fibrocell Science Inc.
EXTON, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007
25 oct. 2018 08h00 HE
|
Fibrocell Science Inc.
Company Plans to Submit Phase 3 Protocol to FDA in Fourth Quarter of 2018 and Commence Trial in First Half of 2019 EXTON, Pa., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc....
Fibrocell to Present at Upcoming Industry and Investor Conferences
26 sept. 2018 08h00 HE
|
Fibrocell Science Inc.
EXTON, Pa., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
25 sept. 2018 08h00 HE
|
Fibrocell Science Inc.
EXTON, Pa., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma
05 sept. 2018 08h00 HE
|
Fibrocell Science Inc.
EXTON, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...